Bionano interim CEO buys $4.8K in stock

Bionano Genomics’ interim chief executive increased his indirect stake via a 4,000‑share open-market purchase.

Rhea-AI Filing Summary

Bionano Genomics, Inc. (BNGO) reported that Interim Chief Executive and director Albert Luderer purchased 4,000 shares of common stock on September 4, 2026 in an open market or private transaction. The shares are held indirectly through a Traditional IRA, bringing his indirect holdings in that account to 8,000 shares.

Insider Trade Summary

Net Buyer: 4,000 shares

Net Buy 1 txn

Insider Luderer Albert

Role Interim Chief Executive

Bought 4,000 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	4,000	$1.2112	$5K

Holdings After Transaction: Common Stock — 8,000 shares (Indirect, Traditional IRA)

Key Figures

Shares purchased: 4,000 shares Purchase price per share: $1.2112 per share Total transaction value: $4,844.80 +2 more

5 metrics

Shares purchased 4,000 shares Common stock bought on September 4, 2026

Purchase price per share $1.2112 per share Average price for the September 4, 2026 purchase

Total transaction value $4,844.80 4,000 shares at $1.2112 per share

Shares owned after transaction 8,000 shares Indirectly held through a Traditional IRA after the purchase

Transaction date September 4, 2026 Date of the insider open market or private transaction

Key Terms

Traditional IRA, indirect ownership, open market or private transaction

3 terms

Traditional IRA financial

"The shares are held indirectly through a Traditional IRA"

indirect ownership financial

"The position is reported as indirect ownership through a Traditional IRA"

open market or private transaction financial

"Purchase in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BNGO report for Albert Luderer?

BNGO reported that Interim Chief Executive and director Albert Luderer purchased 4,000 shares of common stock on September 4, 2026 in an open market or private transaction, held indirectly through a Traditional IRA.

At what price were the BNGO shares purchased by the interim chief executive?

Albert Luderer bought the BNGO common shares at an average price of $1.2112 per share on September 4, 2026, according to the Form 4 disclosure.

How many BNGO shares does Albert Luderer hold after this transaction?

Following the September 4, 2026 purchase, Albert Luderer holds 8,000 BNGO common shares indirectly through a Traditional IRA, as reported in the Form 4.

What is the total dollar amount of BNGO stock purchased in this Form 4?

The interim chief executive purchased 4,000 BNGO shares at $1.2112 each, for a total value of approximately $4,844.80, based on the reported per-share price.

Is the BNGO insider ownership reported as direct or indirect?

The 4,000-share BNGO purchase and the resulting 8,000-share position are reported as indirect ownership, held through a Traditional IRA, rather than directly in the insider’s own name.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 04:30 PM Accepted by SEC EDGAR 09/09/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Luderer Albert

(Last) (First) (Middle)

C/O BIONANO GENOMICS, INC.

9540 TOWNE CENTRE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bionano Genomics, Inc. [ BNGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim Chief Executive

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/04/2026		P		4,000	A	$1.2112	8,000	I	Traditional IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Jonathan V. Dixon, Attorney-in-Fact	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)